SandboxAB: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 13: | Line 13: | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluoroquinolones]] for 3 days <br>[[Ofloxacin]] 200–400 mg po bid.<br>[[Ciprofloxacin]] 250 mg bid po or Cipro XR 500 mg q24h<br>[[Levofloxacin]] 250–750 mg po q24'''''<br>OR<br>'''''▸[[β-lactam]] agents for 3-7 days<br>[[Amoxicillin-clavulanate]] 500/125 mg po tid or 875/125 mg po bid <br>[[Cefdinir]] 300 mg po q12h or 600 mg po q24 <br>[[Cefaclor]] 250-500 mg po q8h<br>[[Cefpodoxime-proxetil]] 100-200 mg po q12h'''''<br>'''''Others([[Cephalexin]]250-500 mg po q6h ) not studied well but effective.''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluoroquinolones]] for 3 days <br>[[Ofloxacin]] 200–400 mg po bid.<br>[[Ciprofloxacin]] 250 mg bid po or Cipro XR 500 mg q24h<br>[[Levofloxacin]] 250–750 mg po q24'''''<br>OR<br>'''''▸[[β-lactam]] agents for 3-7 days<br>[[Amoxicillin-clavulanate]] 500/125 mg po tid or 875/125 mg po bid <br>[[Cefdinir]] 300 mg po q12h or 600 mg po q24 <br>[[Cefaclor]] 250-500 mg po q8h<br>[[Cefpodoxime-proxetil]] 100-200 mg po q12h'''''<br>'''''Others([[Cephalexin]]250-500 mg po q6h ) not studied well but effective.''''' | ||
|- | |- | ||
|} | |} | ||
<BR> | |||
< | |||
† Acute uncomplicated cystitis: Premenopausal, nonpregnant women with no known urological abnormalities or comorbidities,postmenopausal women or well-controlled diabetes female patient. | † Acute uncomplicated cystitis: Premenopausal, nonpregnant women with no known urological abnormalities or comorbidities,postmenopausal women or well-controlled diabetes female patient. | ||
Revision as of 05:44, 17 January 2014
‡Avoid if resistance prevalence is known to exceed 20% or if used for UTI in previous 3 months. ♦Pivmecillinam is available in some European countries, not licensed in US.
|